The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM).

被引：0
|
作者：
Nangia, C. S.
Wang, D.
Scarpace, L.
Schultz, L.
Khanshour, A.
Mikkelsen, T.
机构：
[1] Henry Ford Hosp, Detroit, MI 48202 USA
[2] Josephine Ford Canc Ctr, Henry Ford Hlth Syst, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2021
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Bevacizumab and irinotecan in patients with recurrent glioblastoma multiforme (GBM)
    Raval, Sumul N.
    Rule, Amy
    Hwang, Shirley S.
    NEURO-ONCOLOGY, 2006, 8 (04) : 482 - 482
  • [2] Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM)
    Raval, S.
    Hwang, S.
    Dorsett, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM)
    Maron, R.
    Vredenburgh, J. J.
    Desjardins, A.
    Reardon, D. A.
    Quinn, J. A.
    Rich, J. N.
    Gururangan, S.
    Wagner, S. A.
    Salacz, M. E.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Radiographic evaluation of recurrent glioblastoma multiforme (gbm) in patients treated with bevacizumab and irinotecan
    Andre, Jalal
    Spearman, Kenneth
    Lu, Stanley
    Raval, Sumul
    NEURO-ONCOLOGY, 2007, 9 (04) : 575 - 575
  • [5] Radiographic evaluation of recurrent glioblastoma multiforme (GBM) in patients treated with bevacizumab and irinotecan
    Andre, J.
    Spearman, K.
    Lu, S.
    Hwang, S.
    Dorsett, L.
    Raval, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients
    Bruno Carvalho
    Rafaela Gonçalves Lopes
    Paulo Linhares
    Andreia Costa
    Cláudia Caeiro
    Ana Catarina Fernandes
    Nuno Tavares
    Lígia Osório
    Rui Vaz
    Journal of Neuro-Oncology, 2020, 147 : 109 - 116
  • [7] Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients
    Carvalho, Bruno
    Lopes, Rafaela Goncalves
    Linhares, Paulo
    Costa, Andreia
    Caeiro, Claudia
    Fernandes, Ana Catarina
    Tavares, Nuno
    Osorio, Ligia
    Vaz, Rui
    JOURNAL OF NEURO-ONCOLOGY, 2020, 147 (01) : 109 - 116
  • [8] EFFICACY AND TOLERABILITY OF BEVACIZUMAB MONOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED RECURRENT GLIOBLASTOMA MULTIFORME (GBM)
    Francini, E.
    Mazzaroppi, S.
    Salvati, M.
    Caponnetto, S.
    Laera, L.
    Migali, C.
    Bianco, V.
    NEURO-ONCOLOGY, 2014, 16
  • [9] Phase II trial of bevacizumab and erlotinib in recurrent glioblastoma multiforme (GBM)
    Sathornsumetee, Sith
    Vredenburgh, James
    Rich, Jeremy
    Desjardins, Annick
    Quinn, Jennifer
    Bota, Daniela
    Goli, Krishna
    Mathe, Alyssa
    Gururangan, Sridharan
    Friedman, Allan
    Friedman, Henry
    Reardon, David
    NEURO-ONCOLOGY, 2007, 9 (04) : 516 - 516
  • [10] DEVELOPMENT OF A NOVEL BURDEN SURVEY FOR CAREGIVERS OF GLIOBLASTOMA MULTIFORME (GBM) PATIENTS
    Au, Trang
    Bauer, Hillevi
    Ma, Junjie
    Nelson, Ryan
    Watanabe, Alexandre
    Singh, Prianka
    Korytowsky, Beata
    Wilson, Elizabeth
    Willmarth, Nicole
    Cohen, Adam
    Colman, Howard
    Stenehjem, David
    Brixner, Diana
    NEURO-ONCOLOGY, 2017, 19 : 110 - 110
12345